Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Kalvista Pharmaceuticals Inc
(NQ:
KALV
)
11.87
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 9, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Kalvista Pharmaceuticals Inc
< Previous
1
2
3
4
5
6
7
Next >
Stocks That Hit 52-Week Lows On Wednesday
October 05, 2022
Wednesday saw 127 companies set new 52-week lows.
Via
Benzinga
Where KalVista Pharma Stands With Analysts
October 05, 2022
Analysts have provided the following ratings for KalVista Pharma (NASDAQ:KALV) within the last quarter:
Via
Benzinga
Why Is KalVista Pharmaceuticals (KALV) Stock Down 50% Today?
October 04, 2022
KALV stock investors are having a hard day as KalVista Pharmaceuticals just hit the brakes on a crucial clinical study.
Via
InvestorPlace
KalVista Shares Plunge After Ending KVD824 HAE Trial Over Elevated Liver Enzymes In Patients
October 04, 2022
Via
Benzinga
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 05, 2022
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Why KalVista Pharmaceuticals Shares Are Trading Lower By 59%; Here Are 89 Biggest Movers From Yesterday
October 05, 2022
Losers
Via
Benzinga
S&P 500 Rises 100 Points; Nasdaq Up 3%
October 04, 2022
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite climbing more than 300 points on Tuesday.
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
October 04, 2022
Gainers
Via
Benzinga
KalVista Pharma: Q1 Earnings Insights
September 08, 2022
KalVista Pharma (NASDAQ:KALV) reported its Q1 earnings results on Thursday, September 8, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Kalvista Crashes Nearly 60% After Adding HAE Drug To The Scrap Heap
October 04, 2022
The company scrapped its hereditary angioedema drug due to safety issues.
Via
Investor's Business Daily
Why AeroClean Technologies Shares Are Trading Higher By Around 38%, Here Are 58 Stocks Moving In Tuesday's Mid-Day Session
October 04, 2022
Gainers Bit Brother Limited (NASDAQ: BTB) rose 229% to $0.3688 after declining around 14% on Monday.
Via
Benzinga
Stocks That Hit 52-Week Lows On Tuesday
October 04, 2022
On Tuesday, 44 companies hit new 52-week lows.
Via
Benzinga
Nasdaq Surges 350 Points; Crude Oil Rises Sharply
October 04, 2022
U.S. stocks traded higher midway through trading, with the Nasdaq Composite climbing more than 350 points on Tuesday.
Via
Benzinga
FaZe Holdings, AXT And Some Other Big Stocks Moving Lower On Tuesday
October 04, 2022
U.S. stocks traded higher, with the Dow Jones gaining more than 700 points on Tuesday. Here are some big stocks recording losses in today’s session.
Via
Benzinga
US Stocks Open Higher As Dow Jumps 550 Points
October 04, 2022
U.S. stocks traded higher this morning, with the Dow Jones climbing more than 550 points on Tuesday.
Via
Benzinga
Why Kalvista Pharmaceuticals Shares Are Down Over 50%
October 04, 2022
Kalvista Pharmaceuticals Inc (NASDAQ: KALV) shares are trading lower by 52.42% to $6.78 Tuesday morning after the company announced it terminated the KOMPLETE phase 2 clinical trial for KVD824 for the...
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
October 04, 2022
Gainers Avenue Therapeutics (NASDAQ:ATXI) shares moved upwards by 37.7% to $15.85 during Tuesday's pre-market session. The company's market cap stands at $23.3 million.
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
October 04, 2022
Good morning, investor! It's time for a breakdown of the biggest pre-market stock movers traders need to know about for Tuesday!
Via
InvestorPlace
KalVista Pharmaceuticals Announces Termination of KVD824 Phase 2 KOMPLETE Trial for Prophylactic Treatment of Hereditary Angioedema
October 04, 2022
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals to Present at the 2022 HAEi Global Leadership Workshop
September 30, 2022
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals Reports First Fiscal Quarter Results
September 08, 2022
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 02, 2022
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary
August 23, 2022
Via
Benzinga
KalVista Shares Climb As Late-Stage Label Extension Study On Skin Disorder Candidate Kicks-off
August 23, 2022
KalVista Pharmaceuticals (NASDAQ: KALV) has initiated the KONFIDENT-S open label extension (OLE) study for its ongoing Phase 3 study of sebetralstat for the on-demand treatment of hereditary angioedema...
Via
Benzinga
KalVista Pharmaceuticals Announces Initiation of KONFIDENT-S Open Label Extension Study for Sebetralstat in Hereditary Angioedema
August 23, 2022
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Why Pharvaris Stock Crashed — And Why At Least One Analyst Isn't Worried
August 22, 2022
Shares hit their lowest point since November on the FDA's decision in HAE.
Via
Investor's Business Daily
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 02, 2022
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals to Present at 1st Annual H.C. Wainwright Hereditary Angioedema Conference
July 19, 2022
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Recap: KalVista Pharmaceuticals Q4 Earnings
July 07, 2022
KalVista Pharmaceuticals (NASDAQ:KALV) reported its Q4 earnings results on Thursday, July 7, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
KalVista Pharmaceuticals Provides Operational Update and Fiscal Year Financial Results
July 07, 2022
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.